




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Jiang, J., Kanabar, V., Padilla, B., Man, F., Pitchford, S. C., Page, C. P., & Wagner, G. K. (2016). Uncharged
nucleoside inhibitors of -1,4-galactosyltransferase with activity in cells. Chemical communications (Cambridge,
England), 52(20), 3955-3958. 10.1039/c5cc09289b
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
This journal is©The Royal Society of Chemistry 2016 Chem. Commun., 2016, 52, 3955--3958 | 3955
Cite this:Chem. Commun., 2016,
52, 3955
Uncharged nucleoside inhibitors of b-1,4-
galactosyltransferase with activity in cells†
Jingqian Jiang,a Varsha Kanabar,b Beatriz Padilla,b Francis Man,b
Simon C. Pitchford,b Clive P. Pageb and Gerd K. Wagner*a
We report 5-substituted uridine derivatives as novel, uncharged
inhibitors of b-1,4-galactosyltransferase and chemical tools for
cellular applications. The new inhibitors reduce P-selectin glyco-
protein 1 (PSGL-1) expression in human monocytes. Our results also
provide novel insights into a unique mode of glycosyltransferase
inhibition.
Glycosyltransferases (GTs) are carbohydrate-active enzymes that
catalyze the transfer of a sugar from a glycosyl donor, usually a
sugar-nucleotide, to a suitable acceptor, e.g. another sugar, peptide,
protein, lipid or smallmolecule.1–3 The biosynthetic products of GTs
are involved in many fundamental biological processes, from cell
adhesion4 to bacterial virulence.5 Small molecular GT inhibitors
would enable the manipulation of these processes in an opera-
tionally simple, reversible, time- and concentration-dependent
manner, and are therefore sought after as tool compounds for
chemical biology, drug discovery and biotechnology.
A classical strategy for the development of GT inhibitors is the
modification of the natural sugar-nucleotide donor.6 We have
recently reported 5-substituted derivatives of the sugar-nucleotide
UDP-galactose (UDP-Gal), exemplified by 5-(5-formylthien-2-yl)
UDP-Gal 1 (Fig. 1), as a new class of potent galactosyltransferase
(GalT) inhibitors.7–9 GalTs are a sub-family of GTs, which catalyse
the transfer of D-galactose from UDP-Gal to a specific acceptor.10
Structural and mechanistic studies with a representative blood-
group GalT have shown that the 5-substituent in 1 blocks the
movement of a flexible loop in the enzyme active site during the
catalytic cycle.7,9 Hydrogen bonding and p–p stacking interac-
tions between the 5-(5-formylthien-2-yl) substituent in 1 and the
GalT C-terminus and active site loop are essential for this new
mode of inhibition.7,9
While 1 is a potent inhibitor of various GalTs in vitro, the
presence of the charged pyrophosphate linkage limits its
applicability in cell assays. This is a general problem in GT
inhibitor discovery, as the pyrophosphate linkage is a key
feature of most donor-based GT inhibitors reported to date.6
While there are individual examples for uncharged pyrophos-
phate mimicry,11 and despite recent progress in this area,12
there is presently no general, uncharged bioisostere for the
pyrophosphate group. The complete removal of the pyrophos-
phate linkage on the other hand usually leads to a dramatic loss
of activity. Indeed, no inhibitors based only on the nucleoside
part of a given GT donor, i.e. lacking the pyrophosphate group,
have been reported to date for any GT. Such uncharged nucleo-
side inhibitors promise to oﬀer important advantages for
practical applications, such as improved stability and cell
penetration.
Herein, we describe the first nucleoside inhibitors in the GT
family. We have developed derivatives of 1 which contain an
optimised 5-substituent, but lack the D-galactose and pyrophos-
phate moieties. These 5-substituted uridine derivatives act as
inhibitors of b-1,4-galactosyltransferase (b-1,4-GalT), but are
inactive against a related a-1,4-GalT which uses the same
UDP-Gal donor. Our results provide important insights into
the structural factors that determine activity and target selectivity
in this new GT inhibitor class. We also show that a representative
Fig. 1 Prototype GalT inhibitor 1, and the corresponding nucleoside
derivative 2a.
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inhibitor in this new series reduces the expression of the cell
surface glycoprotein P-selectin glycoprotein ligand-1 (PSGL-1) in
human monocytes. The new inhibitors will therefore be valuable
as novel tool compounds for cellular applications.
In an initial attempt to obtain an uncharged inhibitor of
b-1,4-GalT, we formally removed the pyrophosphate and
D-galactose moieties in 1. However, while 1 inhibits b-1,4-GalT
with an IC50 value of 12 mM, the corresponding uridine derivative
2a is inactive at concentrations up to 1 mM (Fig. 1). In order to
overcome the dramatic drop in activity resulting from removal
of the pyrophosphate linkage and D-galactose, we sought to
optimise the 5-substituent in 2a. We therefore prepared a series
of uridine derivatives with diﬀerent aromatic and heteroaromatic
substituents in position 5 (Scheme 1, 2b–j). The target molecules
were obtained by Suzuki–Miyaura coupling of 5-iodouridine with
different aryl and heteroaryl boronic acids (Scheme 1). We7–9 and
others13,14 have previously reported conditions for the cross-
coupling of unprotected uridine nucleosides and nucleotides
in aqueous media. It is well known that electron-deficient
(hetero)aryl boronic acids tend to react sluggishly in cross-
coupling reactions under conventional heating.15 In order to
facilitate the cross-coupling of such less reactive boronic acids,
we explored suitable microwave conditions for the Suzuki–
Miyaura reaction of 5-iodouridine. For 5-formylthien-2-yl boronic
acid, microwave conditions led to markedly improved yields, from
26% to 54%, and significantly reduced reaction times, from 2 days
to 0.5 h, compared to conventional heating (Table S1, entries 1 and
2, ESI†). These general conditions, employed with several slightly
different catalytic systems, allowed the generation of a family of
5-substituted uridines (Table S1, ESI†). Although yields were
variable, this method allowed the rapid generation of each uridine
derivative in sufficient quantities for biological testing.
In order to generate additional structural diversity, we next
subjected 5-(5-formylthien-2-yl) uridine 2a to reductive amination
with several amino acids16 (Scheme 1, 3a–e). We speculated that
through extension of the 5-substituent, these derivativesmight be
able to pick up additional interactions with the target enzyme
b-1,4-GalT. For these modifications, amino acids with different
side chain functionalities were chosen, including glutamic acid,
lysine, tryptophan and valine. The isolated yields of the reductive
amination products were generally modest, ranging from
18–68% (Table S2, ESI†).
In order to assess the inhibitory activity of our collection of
5-substituted uridine derivatives towards b-1,4-GalT, we used a
biochemical assay, which we have recently adapted for inhibitor
experiments.17 In this colorimetric assay, the phosphate groups
of the secondary GT reaction product UDP are cleaved by a
phosphatase, and the resulting inorganic phosphate is quanti-
fied with malachite green.17 To quantify inhibitory activity of
candidate molecules, we determined IC50 values at enzyme
turnover rates between 20–50% of UDP-Gal donor (ESI†). We have
previously established that this turnover window gives reproducible
and comparable results.17
In the first round of screening, uridine derivatives 2a–g and
3a–e were tested against b-1,4-GalT under these conditions
(Table S3, ESI†). While most of these derivatives were inactive
at concentrations up to 1 mM, 2e and 3e showed promising
inhibitory activity (Table 1). Intriguingly, the 5-substituent of
both of these derivatives contains an indole motif. We therefore
synthesised another three uridine derivatives specifically with
an indole substituent in position 5 (Table S3, ESI†, 2h–j).
Encouragingly, two of these derivatives showed comparable
or better activity than 2e and 3e, suggesting that an indole
substituent in position 5 is indeed advantageous for inhibitory
activity in this series.
Next, we wanted to assess if these new b-1,4-GalT inhibitors
may also be active in cells. In humans, b-1,4-GalT is required
for the formation of the glycan epitope Sialyl Lewis X (sLex) on
Scheme 1 Synthesis of uridine derivatives 2 and 3. Reagents and conditions:
(i) boronic acid, Pd catalyst, ligand, base, solvents, microwave irradiation;
(ii) amino acids, NaBH3CN, MeOH, rt, 1 d. For details and individual yields
see ESI,† for R1/R2 see Table S3 (ESI†).
Table 1 Inhibitory activity of 5-substituted uridine derivatives 2e and 3e,





Uridine H (2e) 207  37 41000
H (3e) 284  26 41000
UDP-Gal a-D-Gal-PP (5) 41  12 54  13
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PSGL-1, a key adhesion molecule involved in inflammatory
cell recruitment into tissues.18 The expression of PSGL-1 in
human monocytes is upregulated upon treatment of cells with a
pro-inflammatory stimulus such as IL-1b. Using an established
FACS-based assay (ESI†),19 we tested the eﬀect of the representative
inhibitor 2e on basal (no IL-1b-stimulation) and IL-1b-induced
PSGL-1 expression in human monocytes.
Under either of these conditions, 2e showed no eﬀect on
PSGL-1 expression (Fig. 2A). We reasoned that this lack of
activity may be due to the limited cell uptake of this uncharged,
but still relatively polar nucleoside. Taking advantage of
the absence of the synthetically problematic D-galactose and
pyrophosphate moieties, we converted 2e into its fully acetylated
pro-drug 4 in a single synthetic step (Scheme S1, ESI†). The use
of peracetylated sugars and nucleosides is a well established
pro-drug strategy, as the acetyl groups are readily removed by
intracellular carboxylesterases.20
Pleasingly, at a concentration of 100 mM, 4 reduced excess
PSGL-1 expression in IL-1b-stimulated hPBMCs to basal levels,
but did not aﬀect PSGL-1 expression in unstimulated hPBMCs
(Fig. 2B). This pronounced and selective inhibition of PSGL-1
expression in cells is consistent with the b-1,4-GalT inhibitory
activity of 2e in vitro. These results therefore suggest that
pro-drug 4 is readily taken up into cells and converted intra-
cellularly into its parent compound 2e, which very likely is the
actual active species. Importantly, at the concentrations used in
the PSGL-1 expression assay, neither 2e nor 4 aﬀected the cell
viability of hPBMCs (ESI†).
5-FT UDP-Gal 1 is a broad-spectrum GalT inhibitor with
activity against several diﬀerent GalTs.7,8 In order to gain
insight into the target selectivity of the new nucleoside-based
inhibitors, we also tested 2e and 3e against the a-1,4-GalT LgtC
from Neisseria meningitidis,21 which uses the same UDP-Gal
donor substrate as b-1,4-GalT. Both 2e and 3e were inactive
against LgtC at the highest concentration tested (Table 1).
This result suggests that removal of the sugar diphosphate
motif does not only represent a strategy to identify inhibitors
with better access to cells, but also oﬀers an opportunity to
achieve target selectivity between diﬀerent GalTs.
In order to better understand the respective contribution of
the 5-substituent and the pyrophosphate and D-galactose groups
to GalT inhibition, we also prepared the UDP-Gal derivatives
corresponding to 2e and 3e. These new UDP-Gal derivatives 5
and 6 (Scheme S2, ESI†) were obtained using a modification
of our previous synthetic route towards such 5-substituted
UDP-sugars.7,8 Thus, the 5-substituent was introduced by cross-
coupling of 5-iodo UMP phosphoromorpholidate, followed by
pyrophosphate bond formation with galactose-1-phosphate
(Scheme S2, ESI†).
As anticipated, the addition of the pyrophosphate and
D-galactose groups improved inhibitory activity against b-1,4-
GalT (Table 1). Thus, UDP-sugars 5 and 6 were 5-fold more
active than the corresponding nucleosides 2e and 3e. Intriguingly,
however, the rank order within the UDP-sugar series was not as
expected. UDP-sugars 5 and 6 were slightly weaker inhibitors of
b-1,4-GalT than the prototype inhibitor 5-(5-formylthien-2-yl)
UDP-Gal 1, even though the corresponding nucleosides 2e and
3e are superior to 5-(5-formylthien-2-yl) uridine 2a (Table 1 and
Fig. 1). Equally interestingly, in contrast to the corresponding
nucleosides, the UDP-Gal derivatives showed no selectivity for
b-1,4-GalT, and were also active against a-1,4-GalT, with very
similar potency (Table 1).
These results suggest that the contribution to b-1,4-GalT
inhibition of the 5-substituent on the one hand, and the
pyrophosphate and D-galactose groups on the other, is not
additive. Rather, there appears to be a direct interplay for GalT
inhibition between these diﬀerent moieties. In the presence of
the complete UDP-Gal structure, the pyrophosphate group
appears to be the dominant factor for inhibition, which enables
strong inhibition, even if the nature of the 5-substituent is
sub-optimal (cf. 1 vs. 5 and 6). On the other hand, this generic
binding motif also leads to a loss of selectivity, as evidenced by
the indiscriminate activity of 5 and 6 against both GalTs tested.
Fig. 2 Eﬀect of uridine derivative 2e (A) and its pro-drug 4 (B) on cell-surface
PSGL-1 expression in CD14+ human peripheral blood mononuclear cells
(hPBMCs). White bars: unstimulated hPBMCs. Black bars: hPBMCs stimulated
with IL-1b. Values are mean  SD from 5 independent experiments with
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In contrast, in the absence of the pyrophosphate and D-galactose
groups, the nature of the 5-substituent becomes critical not only
for this mode of inhibition in general, but also for inhibitory
potency. In the case of b-1,4-GalT, indole-based 5-substituents
appear to be favourable, probably due to specific interactions
with this target enzyme. For other GalTs, the nature of these
interactions may well be diﬀerent, due to the diﬀerent archi-
tecture of the flexible loop and C-terminal region in diﬀerent
enzymes. The 5-substituted uridine inhibitors therefore provide
an opportunity for the design of target-selective GalT inhibitors.
We have developed the first nucleoside-based inhibitors of
glycosyltransferases. In contrast to previously reported donor-
based GT inhibitors, these nucleosides are uncharged, which
facilitates their application in cell assays. Proof-of-concept
experiments demonstrate that these new inhibitors can indeed
be used to reduce the expression of the cell surface glycoprotein
PSGL-1 in human monocytes. The new inhibitors will therefore
be useful tool compounds for chemical biology and biotechnology,
as well as starting points for drug discovery programmes
searching for novel anti-inflammatory agents. Due to their
fragment-like nature, the new inhibitors can be further optimised
using approaches such as fragment-based design22 and dynamic
combinatorial chemistry. Eﬀorts in this direction are currently
underway.
We are grateful to the volunteers who donated blood samples
for this study. We thank King’s College London for a PGR
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gifts from Dr Christelle Breton, Grenoble (b-1,4-GalT) and
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